CSL Half Year Result - CSL beats expectations & assimilates Novartis flu business


CSL, the blood products and vaccine maker, posted a better than expected 3.8% lift in half year profit to US$718.8 million For more Reporting Season coverage, please visit (VIEW LINK)


CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...

earnings commsec reporting season ASX:CSL csl


Please sign in to comment on this wire.